30 August 2013 | News | By BioSpectrum Bureau
Australia-based Nanosonics' disinfection technology trophon EPR gets marketing approval from Korean Food and Drug Administration (KFDA)
Singapore: The Korean Food and Drug Administration (KFDA) has approved Australia-based medical device firm Nanosonics' disinfection technology trophon EPR to be marketed in the country. Nanosonics recently appointed Cochlear senior executive Mr Michael Kavanagh as its CEO to drive its new stage of growth and expansion.
â€œWe are delighted to receive regulatory approval in South Korea, well ahead of schedule. South Korea is a strong and growing market for medical devices. The speed of approval is a testament to the quality of our Regulatory and Product Development teamsâ€ said Dr Ron Weinberger, president, technology development and commercialization, Nanosonics.
â€œExpanding into new geographic markets will drive the next phase of market adoption of the trophon EPR as we continue the goal to see our technology accepted as the global standard of care. We are presently in discussions with potential partners for distribution. These discussions are progressing well and there is strong interest from a number of internationally recognised companies,â€ he added.
Nanosonics has also filed for regulatory approval in Mexico and Japan.